Brodalumab: An evidence-based review of its potential in the treatment of moderate-to-severe psoriasis

• Type: Another Publication in an International Scientific Journal
• Date: 2014

Authors

Coimbra, S (Author) Other; Figueiredo, A (Author) Other; Santos Silva, A (Author) FFUP

Journal

Title: Core Evidence

Vol. 9

Pages: 89-97

ISSN: 1555-1741

Publisher: Core Medical Pub

Indexing

ISI Web of Knowledge

Scopus - 19 Citations

Other information

Authenticus ID: P-009-PX6

DOI: 10.2147/ce.s33940

Abstract (EN): Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis. © 2014 Coimbra et al.

Language: English

Type (Professor's evaluation): Scientific